Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

Background: BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests the existence of genetic and nongenetic modifying factors. In this study, we evaluated the putative role of variants in many candidate modifier genes. Methods: Genotyping data from 15,252 BRCA1 and 8,211 BRCA2 mutation carriers, for known variants (n = 3,248) located within or around 445 candidate genes, were available through the iCOGS custom-designed array. Breast and ovarian cancer association analysis was performed within a retrospective cohort approach. Results: The observed P values of association ranged between 0.005 and 1.000. None of the variants was significantly associated with breast or ovarian cancer risk in either BRCA1 or BRCA2 mutation carriers, after multiple testing adjustments. Conclusion: There is little evidence that any of the evaluated candidate variants act as modifiers of breast and/or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers. Impact: Genome-wide association studies have been more successful at identifying genetic modifiers of BRCA1/2 penetrance than candidate gene studies. Cancer Epidemiol Biomarkers Prev; 24(1); 308–16. ©2014 AACR.

W. Chung | R. Nussbaum | D. Steinemann | F. Couch | J. Chang-Claude | O. Olopade | T. Rebbeck | B. Karlan | J. Benítez | R. Eeles | A. Spurdle | M. Southey | F. Lose | D. Easton | G. Rennert | P. Pharoah | M. Greene | K. Offit | A. Antoniou | Å. Borg | S. Buys | D. Eccles | D. Evans | G. Chenevix-Trench | H. Nevanlinna | U. Hamann | Ana-Teresa Maia | C. Lázaro | K. Nathanson | S. Orsulic | J. Garber | M. Schmidt | Andrew Lee | K. Aittomäki | H. Meijers-Heijboer | A. Meindl | R. Schmutzler | Xianshu Wang | A. Rudolph | I. Andrulis | G. Glendon | A. Mulligan | P. Radice | P. Peterlongo | S. Manoukian | A. Jakubowska | J. Lubiński | K. Durda | A. Toland | F. Fostira | J. Simard | S. Neuhausen | C. Sutter | S. Wang-gohrke | M. Robson | L. McGuffog | A. Godwin | J. Brunet | E. Friedman | M. Friedlander | A. Osorio | N. Ditsch | H. V. van Doorn | S. Tchatchou | B. Wappenschmidt | S. Domchek | D. Stoppa-Lyonnet | N. Lindor | M. Porteous | A. Viel | A. Martayan | G. Giannini | D. Frost | O. Sinilnikova | S. Mazoyer | C. Houdayer | C. Engel | C. Singer | C. Szabo | K. Claes | J. Rantala | R. Platte | B. Arun | U. Jensen | F. Damiola | A. Arason | O. Díez | P. Pujol | S. Hodgson | K. Moysich | L. Walker | Bowang Chen | G. Scuvera | L. Side | T. Hansen | B. Buecher | A. Gerdes | M. Ausems | D. Goldgar | K. Kuchenbaecker | M. Thomassen | Liying Zhang | B. Ejlertsen | M. Vreeswijk | J. Collée | J. Lester | T. Cole | C. Cybulski | M. Teixeira | A. Brady | M. Rogers | A. Bojesen | A. Miron | J. Weitzel | K. Blazer | M. Tischkowitz | J. Chiquette | N. Hoogerbrugge | O. Caron | B. Bressac-de Paillerets | K. Kast | K. Rhiem | S. Wilkening | B. Peissel | A. H. van der Hout | P. Morrison | C. Phelan | J. Gronwald | M. Rookus | L. Feliubadaló | L. Izatt | T. V. van Os | E. Oláh | C. Brewer | R. Davidson | C. Olswold | P. Soucy | D. Barrowdale | S. Healey | M. Piedmonte | I. Blanco | M. Montagna | E. J. van Rensburg | R. Janavicius | S. Ellis | J. Adlard | J. Cook | A. Donaldson | C. Delnatte | I. Coupier | L. Venat-Bouvet | L. Papi | M. Tibiletti | N. Arnold | A. Gehrig | D. Niederacher | H. Plendl | R. Varon‐Mateeva | G. Rodriguez | C. Rappaport | G. Pfeiler | M. Tea | Y. Laitman | I. Pedersen | L. Jønson | Y. Ding | P. Mai | M. de la Hoya | C. M. Dorfling | J. Barwell | M. Barile | N. Boutry‐Kryza | M. Belotti | L. Golmard | L. Walker | V. Joseph | G. Sukiennicki | A. Berger | L. Barjhoux | A. Vratimos | M. S. Askmalm | H. Ehrencrona | D. Zaffaroni | M. J. Kennedy | Daphne Geschwantler Kaulich | L. Copeland | T. Van Maerken | P. Segura | F. H. van der Baan | M. Corines | F. Mariette | S. Fortuzzi | Claire Foo | A. Lee | Filomena Ficarazzi | Lauren M. Jacobs | A. von Wachenfeldt | C. Martínez‐Bouzas | L. Matricardi | Katarzyna Jaworska–Bieniek | E. G. Gómez Garcia | Edye E Conway | T. Cole | J. Cook | M. Kennedy | Capucine Delnatte | Radka Platte | Steve Ellis | Muriel Belotti | E. Friedman | Stefano Fortuzzi | M. Teixeira | Curtis L. Olswold | Johanna Rantala | D. Evans | Frederieke H. van der Baan

[1]  U. Vogel,et al.  Association between Polymorphisms in Glutathione Peroxidase and Selenoprotein P Genes, Glutathione Peroxidase Activity, HRT Use and Breast Cancer Risk , 2013, PloS one.

[2]  J. Chang-Claude,et al.  A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk , 2013, Human molecular genetics.

[3]  D. Altshuler,et al.  Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk , 2013, PLoS genetics.

[4]  D. Easton,et al.  Evaluation of Association Methods for Analysing Modifiers of Disease Risk in Carriers of High‐Risk Mutations , 2012, Genetic epidemiology.

[5]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR 2 associated with risk of sporadic postmenopausal breast cancer , 2012 .

[6]  Christiana Kartsonaki,et al.  A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population , 2010, Nature Genetics.

[7]  J. Hesketh,et al.  Polymorphisms in the selenoprotein S and 15-kDa selenoprotein genes are associated with altered susceptibility to colorectal cancer , 2010, Genes & Nutrition.

[8]  Theodore R Holford,et al.  Molecular and Cellular Pathobiology Transcriptional Profiling Analyses , 2022 .

[9]  V. Pankratz,et al.  Evidence for SMAD 3 as a modifier of breast cancer risk in BRCA 2 mutation carriers , 2010 .

[10]  David N. Rider,et al.  Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies , 2008, Breast Cancer Research.

[11]  J. Brisson,et al.  Vitamin D Pathway Polymorphisms in Relation to Mammographic Breast Density , 2008, Cancer Epidemiology Biomarkers & Prevention.

[12]  M. Pike,et al.  IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3) , 2008, PloS one.

[13]  J. Brisson,et al.  Genetic Polymorphisms Involved in Insulin-like Growth Factor (IGF) Pathway in Relation to Mammographic Breast Density and IGF Levels , 2008, Cancer Epidemiology Biomarkers & Prevention.

[14]  C. Begg,et al.  Variation of breast cancer risk among BRCA1/2 carriers. , 2008, JAMA.

[15]  D. Grobbee,et al.  Common genetic variation in the IGF-1 gene, serum IGF-I levels and breast density , 2008, Breast Cancer Research and Treatment.

[16]  F. Couch,et al.  RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. , 2007, American journal of human genetics.

[17]  B. Ponder,et al.  Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Georgia Chenevix-Trench,et al.  An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) , 2007, Breast Cancer Research.

[19]  E. Friedman,et al.  Cancer risks among BRCA1 and BRCA2 mutation carriers , 2007, British Journal of Cancer.

[20]  J. Simard,et al.  Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. , 2003, Endocrine reviews.